New hope for heart bypass patients: drug targets dangerous low blood pressure
NCT ID NCT07671365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Angiotensin II for patients who develop dangerously low blood pressure after heart bypass surgery. About 329 adults will receive the drug along with standard treatments, and their outcomes will be compared to similar patients from the past. The goal is to see if the drug helps more people survive and recover faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Angiotensin II (Giapreza)
What this could lead to
If successful, this could provide a standard treatment for dangerous low blood pressure after heart bypass surgery, potentially saving lives and reducing time in the hospital.
What could go wrong
This is a single-center trial comparing results to past patients, not a randomized controlled study, so results may be less reliable. The drug may not improve survival or could cause side effects like excessive blood pressure or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.